PPARG and atrial fibrillation: PPAR‐γ agonists, such as pioglitazone, reduce atrial remodeling and AF duration significantly, potentially through antioxidant, anti‐inflammatory, and anti‐apoptotic mechanisms (Liu, Liao, Yang, & Tang, 2016; Xu et al., 2012).